---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-213132"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2024-09-04T23:59:59+00:00"
generated_at: "2026-05-31T06:28:08.565808+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# IN8bio cuts workforce 49%, suspends GBM trial to focus on AML therapy INB-100

## Summary
- Workforce reduced from 37 to 19 FTEs; exec/board take 11% cash compensation cut.
- One-time severance costs of ~$0.3M expected in Q3 2024.
- INB-100 Phase 1 AML trial shows 100% relapse-free survival at median 18.7 months follow-up; expansion cohort targeting ~25 patients by H1 2025.
- Enrollment suspended in INB-400 Phase 2 GBM trial; IN8bio will monitor existing patients and explore partnerships.
- Company exploring other strategic alternatives to preserve cash.

## SEC filing metadata
- accession: 0001193125-24-213132
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2024-09-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312524213132/0001193125-24-213132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312524213132/d855704d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-213132
- JSON: https://secwatch.observer/filing/0001193125-24-213132.json
- Plain text: https://secwatch.observer/filing/0001193125-24-213132.txt

## Key facts
- Restructurings & Charges
  IN8BIO, INC. announced a restructuring with charges of approximately $0.3 million affecting all functional areas, New York City and Birmingham, Alabama sites (from 37 to 19 full-time employees).
  - Type: restructuring
  - Charge: approximately $0.3 million
  - Affected area: all functional areas, New York City and Birmingham, Alabama sites
  - Headcount: from 37 to 19 full-time employees
  source text: such employee’s execution of a separation agreement, which includes a general release of claims against the Company. The Company expects to incur one-time costs of approximately $0.3 million in connection with this workforce reduction, of which nearly all are cash expenditures related to severance. The Company communicated the workforce reduction on September 4, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1740279/000119312524213132/0001193125-24-213132-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.